The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Daiichi Sankyo Pharmaceutical; Gilead Sciences; Novartis
Travel, Accommodations, Expenses - Novartis
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.
 
Chiara Molinelli
Honoraria - Lilly O.
Speakers' Bureau - Novartis Italy
Travel, Accommodations, Expenses - Gilead Sciences; Novartis Italy
 
Flavia Jacobs
No Relationships to Disclose
 
Elisa Agostinetto
Honoraria - AstraZeneca; Lilly; Sandoz
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Genetic Spa; Novartis
 
Guilherme Nader Marta
Travel, Accommodations, Expenses - Bayer; Roche
 
Marcello Ceppi
No Relationships to Disclose
 
Marco Bruzzone
No Relationships to Disclose
 
Eva Blondeaux
Research Funding - Gilead Sciences
 
Francesco Schettini
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Giuseppe Viale
Honoraria - Daiichi Sankyo Europe GmbH
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Research Funding - AstraZeneca (Inst); Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Pfizer; Roche
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo; Daiichi Sankyo; Ipsen; Knight Therapeutics; Libbs; Lilly; Novartis; Pfizer; Roche; Sandoz; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Evandro de Azambuja
Honoraria - Libbs (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech; SeaGen; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca (Inst); Libbs; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech